QLife
Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration
Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will focus on the commercialization of specific disease areas within the Egoo Health platform.
"We are pleased to see growing interest in the Egoo Health platform, particularly as we transition the company toward commercialization. We believe it is realistic for the company to establish partnerships with leading companies in specific disease fields this year. This LOI represents an important first step in executing our partnership strategy."- says Thomas Warthoe CEO of Qlife.
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 2025-01-28 09:00 CET.
| Datum | 2025-01-28, kl 09:00 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.